CareCloud (NASDAQ:CCLD - Get Free Report) is projected to issue its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to announce earnings of $0.12 per share and revenue of $33.50 million for the quarter. CareCloud has set its FY 2026 guidance at 0.200-0.230 EPS. Individuals may review the information on the company's upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:30 AM ET.
CareCloud (NASDAQ:CCLD - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.06 earnings per share for the quarter, beating analysts' consensus estimates of $0.02 by $0.04. The company had revenue of $31.88 million for the quarter, compared to analysts' expectations of $31.85 million. CareCloud had a return on equity of 27.07% and a net margin of 6.21%. On average, analysts expect CareCloud to post $0.37 EPS for the current fiscal year and $0.46 EPS for the next fiscal year.
CareCloud Stock Up 1.7%
Shares of NASDAQ CCLD opened at $1.77 on Thursday. The company has a market capitalization of $75.21 million, a price-to-earnings ratio of 25.29 and a beta of 1.51. The company has a debt-to-equity ratio of 2.20, a current ratio of 1.02 and a quick ratio of 1.01. The business has a 50-day moving average of $2.10 and a two-hundred day moving average of $2.50. CareCloud has a 1 year low of $1.70 and a 1 year high of $3.81.
Wall Street Analyst Weigh In
Several equities research analysts have recently weighed in on the company. Roth Capital dropped coverage on CareCloud in a research report on Tuesday, September 15th. They set a "neutral" rating on the stock. Prior estimates, ratings, and price targets should no longer be relied upon. Weiss Ratings raised CareCloud from a "hold (c-)" rating to a "hold (c)" rating in a report on Monday, October 12th. Finally, Wall Street Zen upgraded shares of CareCloud from a "hold" rating to a "buy" rating in a research note on Saturday, August 8th. One research analyst has rated the stock with a Buy rating and one has given a Hold rating to the company's stock. Based on data from MarketBeat.com, CareCloud has a consensus rating of "Moderate Buy".
Check Out Our Latest Analysis on CareCloud
About CareCloud
(
Get Free Report)
CareCloud, Inc NASDAQ: CCLD provides cloud-based health care information technology and revenue cycle management services to medical practices, hospitals and other health care organizations. The company's solutions are designed to help providers manage administrative, clinical and financial operations through integrated software and technology-enabled services.
Its offerings include electronic health records, practice management, medical billing and revenue cycle management, patient engagement tools, telehealth capabilities and related health care technology services.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider CareCloud, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CareCloud wasn't on the list.
While CareCloud currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.